<DOC>
	<DOCNO>NCT01430000</DOCNO>
	<brief_summary>Patients complete conventional treatment HCV relapse ( virus appear blood ) effective therapy .</brief_summary>
	<brief_title>Safety Efficacy Sustained Interferon Alfa 2b ( INF ) Therapy Relapsing Hepatitis C ( HCV ) Patients Using InfraDure Biopump</brief_title>
	<detailed_description>The rational behind propose study patient tolerate prolonged IFN injection side effect . The new propose treatment allow continous low dos IFN secrete patient use skin dermo fibroblast enrich human gene erythropoietin . The `` biopump '' continue secret IFN several month avoid spike IFN plasma beleived cause undesired effect . Patients able complete long treatment low IFN dose Ribavirin hop induce prolong remission cure</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Signed patient consent form Chronic HCV patient relapse follow conventional treatment regimen ( INF+Ribavirine ) detectable plasma level HCV RNA Hepatitis B human immunodeficiency virus negative screen visit Able willing follow contraception requirement Screening laboratory value , test , physical exam within acceptable range Current enrollment another investigational device drug study Anticipated inability complete clinic visit comply study procedure History , current medical condition , could impact safety subject study Autoimmune hepatitis , suspect hepatocellular carcinoma , decompensated liver disease , know liver disease HCV Alcoholism substance abuse &lt; 6 documented month sobriety Known allergy sensitivity interferon ribavirin Any condition , opinion Investigator , would make subject unsuitable enrollment could interfere subject participate completing study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>